CG Oncology, Inc. (CGON)
2025-03-31 | 2024-09-30 | |||
|---|---|---|---|---|
| License and collaboration revenue | 52 | 43 | ||
| Research and development | 27,467 | 19,622 | ||
| General and administrative | 14,789 | 8,716 | ||
| Total operating expenses | 42,256 | 28,338 | ||
| Loss from operations | -42,204 | -28,295 | ||
| Other income (expense), net | 5 | -2 | ||
| Interest income, net | 7,747 | 7,892 | ||
| Total other income, net | 7,752 | 7,890 | ||
| Net loss and comprehensive loss | -34,452 | -20,405 | ||
| Net loss attributable to common stockholders | - | -20,405 | ||
| Basic eps | -0.45 | -0.3 | ||
| Diluted eps | -0.45 | -0.3 | ||
| Basic average shares | 76,187,621 | 67,143,744 | ||
| Diluted average shares | 76,187,621 | 67,143,744 | ||